Every Form 4 that Generate Biomedicines, Inc. (GENB) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow GENB and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full GENB filings page.
Generate Biomedicines, Inc. (GENB) director Frances Arnold reported a sale of 1,000 shares of common stock on September 1, 2026 at a weighted average price of $16.002 per share, effected under a Rule 10b5-1 trading plan adopted on March 13, 2026. After this sale, she holds 231,472 shares directly and an additional 232,472 shares are held indirectly by The Frances Arnold 2010 Irrevocable Trust, for which she disclaims beneficial ownership except to the extent of any pecuniary interest.
Generate Biomedicines, Inc. Chief Executive Officer Michael Nally purchased 20,000 shares of common stock in an open-market transaction at $12.00 per share. Following this purchase, he directly owned 572,707 common shares, with additional indirect holdings reported through the MTN 2024 GST Trust and MTN 2024 GRAT.
Vessey Rupert reported acquisition or exercise transactions in this Form 4 filing.
Generate Biomedicines director Rupert Vessey was granted a new stock option award. The Form 4 reports an option over 29,561 shares of Generate Biomedicines, Inc. common stock, held directly. Following this grant, he holds 29,561 derivative securities.
The footnote states that all shares underlying this option will vest in full on February 19, 2027, provided he continues to serve through that vesting date. This is an equity compensation grant rather than an open-market share purchase or sale.
Generate Biomedicines, Inc. Chief People Officer Beth Grous reported two insider transactions. An account held by her spouse bought 300 shares of common stock at $16.00 per share, recorded as indirect ownership. She also received a grant of 114,020 stock options, which vest in forty-eight equal monthly installments starting after February 19, 2026, contingent on continued service.
Generate Biomedicines director Frances Arnold received a stock option grant for 29,561 shares. The option was awarded at an exercise price of $0.00 per share and increases her directly held derivative position to 29,561 options. These options are scheduled to vest in full on February 19, 2027, if she continues serving through that date.
Generate Biomedicines, Inc. Chief Medical Officer Laurie Anne Lee reported an award of stock options covering 42,230 shares on February 26, 2026. These options were granted at an exercise price of $0.00 per share and will vest in 48 equal monthly installments following February 19, 2026, as long as she continues in service.
Generate Biomedicines, Inc. reported that Chief Legal Officer & General Counsel Martin Sean received a grant of stock options covering 190,034 shares on February 26, 2026. The award was recorded as a grant or other acquisition, not an open-market purchase. According to the disclosure, the options vest in 48 equal monthly installments starting after February 19, 2026, and each installment requires his continued service on the relevant vesting date.
Generate Biomedicines director Nancy A. Simonian received a stock option grant for 29,561 shares of common stock at an exercise price of $0.00 per share. According to the filing, the option vests in full on February 19, 2027, subject to her continued service on that vesting date.
Generate Biomedicines, Inc. executive Jason Silvers, President & CFO, reported several equity transactions. On March 2, 2026, accounts for his daughter and son bought a total of 2,000 shares of common stock in open-market purchases at $16.00 per share, reported as indirect ownership.
On February 26, 2026, he also received two grants of stock options. One option covers 295,608 shares, vesting in two equal installments on February 19, 2029 and February 19, 2030. The other covers 274,493 shares, vesting in forty-eight equal monthly installments following February 19, 2026, in each case contingent on continued service.
Generate Biomedicines, Inc. reported multiple insider transactions involving entities affiliated with Flagship Pioneering. On March 2, 2026, shares of Series A, B and C preferred stock held by several Flagship funds automatically converted into common stock on a one-for-1.5190 basis upon the closing of the company’s initial public offering.
On the same date, Flagship Pioneering Fund VII, L.P., FPN II, L.P. and Pioneering Medicines 02, LLC each purchased 1,562,500 shares of common stock at $16.00 per share, totaling 4,687,500 shares, all reported as indirect ownership. Separately, on February 26, 2026, Noubar Afeyan received a stock option for 29,561 shares, vesting in full on February 19, 2027, contingent on continued service.
Generate Biomedicines Chief Technology Officer Gevorg Grigoryan reported two grants of stock options to acquire company shares. One option covers 295,608 shares and vests in two equal installments on February 19, 2029 and February 19, 2030, subject to continued service. A second option covers 196,368 shares and vests in forty-eight equal monthly installments following February 19, 2026, also conditioned on his continued service. Both awards are recorded at an exercise price of $0.00 per share, reflecting their nature as compensatory grants rather than open-market purchases.
Generate Biomedicines, Inc. director and CEO Michael Nally reported several insider equity transactions. An entity associated with him, the MTN 2024 GST Trust, converted 1,000,000 shares of Series A Preferred Stock into 658,327 shares of Common Stock at no per-share price upon the company’s initial public offering on March 2, 2026, and he disclaims beneficial ownership of those trust-held shares except for any pecuniary interest.
Separately, Nally received two direct stock option awards, each covering 844,595 shares, on February 26, 2026, as grants at a stated exercise price of $0.00 per share. One option vests in two equal installments on February 19, 2029 and February 19, 2030, and the other vests in 48 equal monthly installments after February 19, 2026, in each case subject to his continued service. As of February 26, 2026, he held 552,707 shares of Common Stock directly and 999,793 shares indirectly through the MTN 2024 GRAT.
Generate Biomedicines director Jane L. Mendillo reported two transactions involving the company’s securities. On March 2, 2026, she made an open-market purchase of 1,500 shares of Common Stock at $16.00 per share, bringing her directly held common shares to 1,500.
On February 26, 2026, she also received a grant of 29,561 stock options with an exercise price of $0.00. According to the disclosure, the shares underlying this option vest in full on February 19, 2027, subject to her continued service with the company on that vesting date.
Fanucci Marsha reported acquisition or exercise transactions in this Form 4 filing.
Generate Biomedicines, Inc. director Marsha Fanucci reported receiving a stock option grant for 29,561 shares on February 26, 2026. The option has a price per share of $0.00, reflecting a compensatory award rather than an open-market purchase. These option shares vest in full on February 19, 2027, if she continues in service through that date.
Generate Biomedicines, Inc. director Parker Paul Gray received a grant of stock options covering 29,561 shares on February 26, 2026. The options were awarded at an exercise price of $0.00 per share as part of his compensation.
The option grant will vest in full on February 19, 2027, as long as Gray continues to serve the company through that vesting date. After this grant, he holds derivative securities representing 29,561 shares directly.
Generate Biomedicines, Inc. reported multiple insider-related transactions involving funds affiliated with Flagship Pioneering. On March 2, 2026, shares of Series A, B and C preferred stock held by these funds automatically converted into common stock on a one-for-1.5190 basis upon the closing of the company’s initial public offering. On the same date, Flagship Pioneering Fund VII, L.P., FPN II, L.P. and Pioneering Medicines 02, LLC each bought 1,562,500 shares of common stock at $16 per share in open-market or private transactions, for a total of 4,687,500 shares purchased. Separately, on February 26, 2026, Noubar Afeyan received a grant of 29,561 stock options that vest in full on February 19, 2027, subject to continued service.